Quality of Practice Domain
Heather Jacene, MD
At the AM, V1IA committee members suggested the following topics:

1. RaPTR+PLUS and RaPTR
2. Radiopharmaceutical Therapy Centers of Excellence
3. Include personalized dosimetry in the RPT Center of Excellence program
4. Create and provide ongoing diagnostic training
5. White paper best practices for radiopharmaceuticals
6. Color-coded system for radiopharmaceuticals
7. Develop pathways for oncology treatment with molecular imaging and report deviations from the pathway
8. MIPS Quality Measures
9. Define standards for drug manufacturing and image acquisition
10. Eliminate institutional controls for data sharing
11. Create a virtual mentor group for technologists
RaPTR+PLUS and RaPTR

RadioPharmaceutical Therapy Registry
The goal of RaPTR and RaPTR+PLUS is to provide the framework to support a community of practices committed to patient-centered imaging and therapy, patient-safety, reduction in radiation dose, improved outcomes, practice transformation and innovation through ongoing data collection, and quality improvement.

RaPTR
- Clinical data only, no imaging data
- Will include $^{177}$Lu-PSMA (Pluvicto) therapy
- In discussion with technology vendors to learn more about EMR integration capabilities.

RaPTR+PLUS
- 4 pilot sites applying for IRB approval, including one VA hospital
- Clinical data collected in REDCap
- Imaging data including PET/CT, SPECT/CT, and planar via MIM Cloud
SNMMI designated Centers of Excellence in Radiopharmaceutical Therapy meet strict regulatory, training, qualification, experience, and performance criteria to help assure patients, their families, referring physicians, and payors that rigorous procedures are in place and followed, leading to appropriate patient selection and outcomes from radiopharmaceutical therapy.
Approved Clinical Sites
- Christiana Care
- Excel Diagnostics and Nuclear Oncology Center
- Hoag Memorial Hospital Presbyterian
- Kettering Health Main Campus
- Northwestern Memorial Hospital
- ARA Theranostics Center

Approved Comprehensive Sites
- Stanford University - Stanford HealthCare
- Dana-Farber / Brigham and Women's Cancer Center
- Memorial Sloan Kettering Cancer Center
- SMM Health St. Louis University Hospital
- University of Minnesota Medical Center
- The Ohio State University Wexner Medical Center
- David Geffen School of Medicine at UCLA
- Duke University Health
- Emory University Hospital
- MD Anderson Cancer Center
- University of Pittsburgh Medical Center
- UCSF
- Mayo Clinic
- Mount Sinai Health System
- University of Iowa
- University of Colorado Anschutz Medical Center

Applications Approved: 26

Approved Basic Therapy Centers
- Beaumont Hospital Royal Oak
- Riley-Tree Cancer Center at Sansum Clinic
- Highlands Oncology Group

9 applications are still pending review
3 applications are on hold
Personalized Dosimetry in RPTCOE


Publication of the Lu177 Dosimetry Challenge Results will inform a Procedure Standard (to be developed) on personalized dosimetry (Quality Domain)
NEW! Live Reader Training with CE at MWM

- Experts will review cases of newer imaging agents with full DICOM cases, e.g., PSMA agents, 18F-FES, etc.
- Learners will have an iPAD with the cases so they can review on their own
- Interactive and effective way of teaching
- Up to 50 attendees
Quality and Safety Initiatives

- Draft and publish a white paper on proper handling and administration of radiopharmaceutical therapies
- Develop a color-coding system for all radiopharmaceuticals to avoid dosing errors
- Landing page for Patient Safety on the new SNMMI web page (2023)
Develop pathways for oncology treatment which include use of molecular imaging.

- Neuroendocrine tumors
- Prostate cancer
- Breast cancer
- Lung cancer
- Lymphoma
- Others

PET/CT
PET/MR
SPECT/CT

Report out deviations from the pathway.
Two quality measures were submitted to CMS for implementation in 2024.

- Comparison of Somatostatin Receptor (SSTR) PET Imaging to Conventional Imaging (Computed Tomography [CT]/ Magnetic Resonance Imaging [MRI]) to Identify De-differentiated NET
- Somatostatin Receptor (SSTR) PET Imaging Scan Prior to Lutathera for Patients with Neuroendocrine Tumors (NET)

Unfortunately, they were not accepted by CMS.

Measure #147 (Bone scan comparison) will be available for 2023.

To support the quality measures development initiative, SNMMI created a new Task Force that will work on creating innovative, practical, and comprehensive measures for the nuclear medicine specialty.
Other Suggestions from AM

- Define standards for drug manufacturing and image acquisition

- Eliminate institutional controls for data sharing
  - This is a lofty goal but is being tackled by the Artificial Intelligence Task Force

- Create a virtual mentor group for technologists
  - This may be better handled in the Work Force Pipeline Domain
What else should we be doing?